- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Strong Balance Sheet Stocks
U.S. Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Results
574
Strong Balance Sheet Stocks: companies with a Health score of at least 4, ordered by Health score.
574 companies
GH Research
Market Cap: US$779.1m
Together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States.
GHRS
US$12.78
7D
5.6%
1Y
29.0%
Astria Therapeutics
Market Cap: US$387.7m
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.
ATXS
US$6.76
7D
1.3%
1Y
-38.9%
Atossa Therapeutics
Market Cap: US$101.5m
Operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.
ATOS
US$0.78
7D
1.0%
1Y
-39.1%
ImmunoPrecise Antibodies
Market Cap: US$91.8m
Operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company.
IPA
US$2.02
7D
9.2%
1Y
124.4%
Stevanato Group
Market Cap: US$6.1b
Engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
STVN
US$22.17
7D
-8.4%
1Y
10.9%
Trevi Therapeutics
Market Cap: US$925.5m
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
TRVI
US$7.49
7D
2.6%
1Y
172.4%
Anbio Biotechnology
Market Cap: US$2.1b
Provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally.
NNNN
US$50.14
7D
8.9%
1Y
n/a
Intellia Therapeutics
Market Cap: US$1.2b
A clinical-stage gene editing company, focuses on the development of curative genome editing treatments.
NTLA
US$10.90
7D
-4.9%
1Y
-52.3%
Dianthus Therapeutics
Market Cap: US$671.1m
A clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.
DNTH
US$20.25
7D
5.7%
1Y
-32.1%
Niagen Bioscience
Market Cap: US$808.8m
Operates as a bioscience company engages in developing healthy aging products.
NAGE
US$9.71
7D
1.0%
1Y
194.7%
MEI Pharma
Market Cap: US$166.4m
A clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer.
MEIP
US$4.90
7D
-3.9%
1Y
54.6%
Boundless Bio
Market Cap: US$26.2m
A clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA).
BOLD
US$1.17
7D
2.6%
1Y
-65.0%
ACADIA Pharmaceuticals
Market Cap: US$4.2b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$24.51
7D
0.5%
1Y
59.2%
Protara Therapeutics
Market Cap: US$125.8m
A clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
TARA
US$3.19
7D
2.9%
1Y
55.6%
Vanda Pharmaceuticals
Market Cap: US$257.6m
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
VNDA
US$4.43
7D
5.5%
1Y
-14.3%
ProKidney
Market Cap: US$693.7m
A clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States.
PROK
US$2.42
7D
-5.7%
1Y
1.3%
Monopar Therapeutics
Market Cap: US$206.8m
A clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
MNPR
US$35.86
7D
-10.6%
1Y
1,413.1%
Qiagen
Market Cap: US$10.7b
Provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally.
QGEN
US$48.96
7D
1.2%
1Y
2.5%
Cellectar Biosciences
Market Cap: US$12.6m
A clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.
CLRB
US$4.42
7D
-6.2%
1Y
-92.7%
Vaxcyte
Market Cap: US$4.1b
A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
PCVX
US$31.43
7D
4.7%
1Y
-59.9%
Pacira BioSciences
Market Cap: US$1.1b
Engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
PCRX
US$24.99
7D
5.1%
1Y
87.2%
Silence Therapeutics
Market Cap: US$276.3m
A biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
SLN
US$5.63
7D
4.6%
1Y
-66.4%
Lantern Pharma
Market Cap: US$51.4m
Focuses on the discovery and development of oncology drug.
LTRN
US$4.57
7D
-8.4%
1Y
6.5%
4D Molecular Therapeutics
Market Cap: US$311.5m
A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
FDMT
US$7.10
7D
22.8%
1Y
-51.6%
Passage Bio
Market Cap: US$19.9m
A genetic medicines company, develops gene therapies for central nervous system diseases.
PASG
US$7.59
7D
35.3%
1Y
-51.3%
InMed Pharmaceuticals
Market Cap: US$2.7m
A clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States.
INM
US$2.34
7D
4.5%
1Y
-18.8%
Ventyx Biosciences
Market Cap: US$203.2m
A clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases.
VTYX
US$3.00
7D
27.1%
1Y
56.3%
Exicure
Market Cap: US$45.2m
Does not have significant operations.
XCUR
US$6.85
7D
-6.9%
1Y
278.3%
Synlogic
Market Cap: US$17.5m
A biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States.
SYBX
US$1.45
7D
6.5%
1Y
2.1%
Propanc Biopharma
Market Cap: US$100.9m
A development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia.
PPCB
US$10.40
7D
70.5%
1Y
-56.6%
Bone Biologics
Market Cap: US$3.8m
A medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein.
BBLG
US$2.35
7D
-7.5%
1Y
-73.4%
Exelixis
Market Cap: US$10.4b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$38.47
7D
2.9%
1Y
46.2%
Biogen
Market Cap: US$19.8b
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
BIIB
US$134.94
7D
5.6%
1Y
-33.1%
Corcept Therapeutics
Market Cap: US$7.7b
Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$72.00
7D
0.7%
1Y
106.1%
Barinthus Biotherapeutics
Market Cap: US$51.3m
A clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases.
BRNS
US$1.28
7D
-12.0%
1Y
-1.9%
HilleVax
Market Cap: US$102.5m
A clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States.
HLVX
US$2.08
7D
1.0%
1Y
14.9%